Stem from our advanced R&D on bacteriophages, our Mission is to develop robust modern solutions to fight drug-resistant infections. Antimicrobial resistance (AMR) is a substantial public health issue. From 700 000/y deaths today, the AMR burden is expected to reach ten million/y deaths by 2050, more than cancer. Our approach is to work on personalized, selective, and specific phage therapies against those multi-resistant bacterial infections.
